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ABSTRACT Ectopic expression of decorin in a wide variety
of transformed cells results in growth arrest and the inability to
generate tumors in nude mice. This process is caused by a
decorin-mediated activation of the epidermal growth factor
receptor, which leads to a sustained induction of endogenous
p21WAF1yCIP1 (the cyclin-dependent kinase inhibitor p21) and
growth arrest. However, mice harboring a targeted disruption of
the decorin gene do not develop spontaneous tumors. To test the
role of decorin in tumorigenesis, we generated mice lacking both
decorin and p53, an established tumor-suppressor gene. Mice
lacking both genes showed a faster rate of tumor development
and succumbed almost uniformly to thymic lymphomas within 6
months [mean survival age (T50) ;4 months]. Mice harboring
one decorin allele and no p53 gene developed the same spectrum
of tumors as the double knockout animals, but had a survival
rate similar to the p53 null animals (T50 ; 6 months). Ectopic
expression of decorin in thymic lymphoma cells isolated from
double mutant animals markedly suppressed their colony-
forming ability. When these lymphoma cells were cocultured with
fibroblasts derived from either wild-type or decorin null em-
bryos, the cells grew faster in the absence of decorin. Moreover,
exogenous decorin proteoglycan or its protein core significantly
retarded their growth in vitro. These results indicate that the lack
of decorin is permissive for lymphoma tumorigenesis in a mouse
model predisposed to cancer and suggest that germ-line muta-
tions in decorin and p53 may cooperate in the transformation of
lymphocytes and ultimately lead to a more aggressive phenotype
by shortening the tumor latency.
Recent advances in the chemistry and biology of extracellular
matrices have strengthened the concept that an understanding of
the mechanisms underlying tumor cell proliferation and invasion
of host tissues requires a knowledge of the complex interactions
between the tumor cells and the surrounding connective tissue.
Proteoglycans are key bioactive molecules that directly affect
neoplastic development. Decorin, a prototype member of an
expanding family of small leucine-rich proteoglycans, regulates
matrix assembly, growth factor activities, and tumor cell growth
(1). The observation that the tumor stroma of human colon
cancer contains increased levels of decorin suggested that the
abnormal expression of this gene would favor growth and infil-
tration of malignant cells (2). However, a mounting body of
evidence indicates that decorin has growth-suppressive proper-
ties. For instance, de novo decorin gene expression totally sup-
presses the malignant phenotype of human colon carcinoma cells:
the cells show a decline in growth rate, do not grow in soft agar,
and fail to generate tumors in immunocompromised mice (3).
The cells are arrested in G1 and can reenter the cell cycle when
decorin expression is abrogated by antisense oligodeoxynucleoti-
des specific for decorin mRNA. This decorin-induced growth
arrest is linked to a marked induction of p21 (4), a gene that is a
potent cyclin-dependent kinase inhibitor (5) and that is transcrip-
tionally induced by p53 (6). These cytostatic effects of decorin so
far appear to be global because ectopic expression of decorin in
transformed cell lines of various histogenetic origins leads to a
marked growth suppression (7). In all stably transfected clones,
growth arrest is associated with induction of p21 and its translo-
cation into the nuclei (7), and p21 gene is required because cells
harboring a disrupted p21 gene fail to be growth-suppressed by
decorin (7). We recently discovered that decorin proteoglycan or
protein core causes a rapid phosphorylation of the epidermal
growth factor (EGF) receptor and a concurrent activation of
mitogen-activated protein kinase signal pathway, which causes a
protracted induction of endogenous p21 and, ultimately, cell cycle
arrest (8). Moreover, decorin induces mobilization of cytosolic
calcium, and this effect is blocked by AG1478, a specific inhibitor
of EGF receptor activity (9).
To establish the role of decorin in development, we generated
mice harboring a targeted mutation of both decorin alleles. These
mutant mice express a skin fragility phenotype with abnormal
tensile strength and deregulated collagen fibrillogenesis (10).
However, the mutant animals do not develop spontaneous tu-
mors, indicating that loss of decorin alone is not sufficient for
tumorigenesis. We hypothesized that if decorin suppresses the
growth of tumor cells, then its absence could favor cancer growth
and invasion, given a suitable genetic background in which
tumorigenesis is favored. To test this hypothesis, we generated
double knockout mice deficient in both decorin and p53, a well
established tumor-suppressor gene that, when genetically dis-
rupted, produces an excellent animal model of tumorigenesis
(11–13). Notably, mice deficient for both genes showed a faster
rate of tumor emergence and developed almost uniformly thymic
lymphomas positive for CD4 and CD8 markers. Mice harboring
one decorin allele and no p53 gene developed the same spectrum
of tumors as the double knockout animals, but had a survival rate
similar to that of the singly p53 null animals. The growth of thymic
lymphoma cells was markedly retarded when decorin was present
as either exogenously supplied or naturally secreted by cocultured
fibroblasts. Also, transient transfection with decorin markedly
(.75%) reduced the colony-forming ability of the lymphoma
cells. These results indicate that lack of decorin is permissive for
lymphoma tumorigenesis and suggest that germ-line mutations of
decorin and p53 may cooperate to decrease the time of overall
tumor development. A functional synergism between a secreted
(‘‘extracellular tumor-repressor’’) and an intracellular (‘‘tumor-
suppressor’’) gene is proposed to play a role in lymphomagenesis.
EXPERIMENTAL PROCEDURES
Materials. Fetal bovine serum (FBS) and fetal calf serum
(FCS), DMEM, Medium 199, Dulbecco’s PBS, and glutamine
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were purchased from Mediatech (Herndon, VA). Gentamycin,
penicillinystreptomycin, and Fungizone were obtained from
GIBCO. LeukoStat Stain Kit was purchased from Fisher Scien-
tific. Antibodies against mouse CD4 and CD8 antigens were from
Southern Biotechnology Associates. Anti-mouse decorin anti-
serum was a gift from L. Fisher, National Institutes of Health.
Recombinant decorin proteoglycan and protein core were puri-
fied from HT-1080 fibrosarcoma cells as described before (14).
Generation of p532y2 Decorin2y2 Animals and Histology.
To investigate possible cooperative effects on tumorigenesis of
germ-line mutations in p53 and Dcn genes, we mated mice
homozygous for p53 mutation (11), purchased from Taconic
Farms (Germantown, NY), with animals homozygous for Dcn
mutation (10) to generate a series of animals heterozygous for
both mutations (p531y2 Dcn1y2). The genotype of the animals
was determined by PCR analysis using specific primers for p53
(15) and Dcn (11) genes. The nature of the amplified bands was
determined by DNA sequencing using the same primers. Double
mutant animals were generated by intercrossing the double
heterozygous according to standard protocols (16). Essentially,
three groups of animals were compared, namely p531y1
Dcn2y2 (n 5 68), p532y2 Dcn 2y2 (n 5 58), and p532y2
Dcn1y2 (n 5 28). These sets of animals were monitored
carefully, and animals exhibiting ill health were sacrificed and
subjected to detailed autopsy. Tissues were fixed immediately in
10% neutral buffered formalin, embedded in paraffin, sectioned
at 8 mm, and stained with hematoxylin and eosin (17). Cytospin
preparations of thymic lymphoma cells were fixed in methanol for
5 min and subjected to immunohistochemical analysis using
anti-CD4 and anti-CD8 antibodies and a detection system as
described before (18).
Establishment of Tumor Cell Lines from Thymic Lymphomas
of Double Mutant Animals. Three independent thymic lym-
phoma cell lines (designated PD85, PD99, and PD100) were
isolated from spontaneously arising thymic lymphomas in
p532y2 Dcn2y2 mice. The tumors were finely minced and the
fragments were placed in a flask with a small amount of medium
to allow attachment of the tissue explants. After 6 days a rapidly
growing adherent population of cells was observed. These cells
could be subcultured readily without trypsin by using Hanks’
balanced salt solution (HBSS) containing 100 mgyml EDTA.
After several subcultures a population of nonadherent lymphoma
cells was isolated and expanded. The cells were grown routinely
to high density in DMEMy10% FBS or Iscove’s modified DMEM
(IDMEM)y10% FBS and passaged at a 1:20 ratio in the same
medium.
Coculture Experiments. Primary cultures of mouse embryo
fibroblasts were prepared as described previously (10). Briefly,
10- to 12-day-old embryos from a timed pregnant mouse were
removed aseptically. The head of the embryo was discarded and
the body was minced finely with scalpels into 1-mm3 fragments.
After thorough rinsing with DMEM, the fragments were placed
in a 25-cm2 flask with a small volume ('1–2 ml) of growth
medium (DMEMy10% FBS) so that the surface tension allowed
the fragments to adhere to the flask. Adherence and initiation of
outgrowth of embryonic fibroblasts usually occurred within
24–36 hr. The cultures reached confluence within a week, after
which they could be subcultured. Verification of the genotype was
done by PCR or Southern blot analysis as described previously
(10). The two established cell lines mouse embryonic fibroblast
(MEF) Dcn1y1 and MEF Dcn2y2 were used as a feeder layer
to test the decorin effect on the growth of PD100 lymphoma cells.
MEF Dcn2y2 and MEF Dcn1y1 cells were grown in DMEM
supplemented with 10% FBS in six-well dishes for 24 hr and then
grown overnight in IDMEM supplemented with 5% FBS. After
reaching confluence the cells were treated with mitomycin (10
mgyml) for 3 hr to block cell division and washed extensively to
remove any residual mitomycin. PD100 lymphoma cells were
seeded at '105 per dish on the top of mitomycin-treated fibro-
blasts, which acted as a feeder layer. The number of the PD100
cells that grew in suspension was determined daily for the
following 5 days. PD100 parental cells were also grown in the
presence of decorin proteoglycan or protein core purified from
human HT1080 as described before (14).
Retroviral Infection and Colony Formation Assay. Because the
double knockout tumor cell lines were resistant to neomycin, we
first transfected by electroporation the PD100 clone with the
full-length mouse decorin using a pCDNA3.1yZeo(1) vector
(CLONTECH). However, several transfection experiments
proved unsuccessful. For this reason, we utilized a retrovirus
approach. The full-length mouse decorin cDNA was subcloned
into the EcoRI restriction site of LXSP retroviral vector (a kind
gift from A. Sacchi, Regina Elena Cancer Institute, Rome), which
carries the puromycin-resistance gene. T cell lymphoma cells
(PD100) obtained from the p532y2 Dcn2y2 double knockout
mice were kept in culture in IMDM supplemented with 10% FBS.
Infection of 2.5 3 106 PD100 cells with the retrovirus carrying the
full-length decorin (LXSP-Decorin) or with the empty virus
LXSP (19) was carried out by cocultivation (20) of the PD100 cells
with 293-derived BOSC 23 packaging cells transiently transfected
by the calcium phosphate precipitation with the retroviral con-
structs mentioned above. Three days postinfection, 5 3 104 viable
cells were plated in semisolid medium [0.9% methyl-cellulose
(Methocult H4100; Stem Cell Technologies) in IMDM with 10%
FCS] in the presence of puromycin (2 mgyml). Colonies (.125
mm) were scored 12 days later.
RESULTS
Accelerated Tumorigenesis and Mortality Rate in p532y2
Dcn2y2 Animals. To investigate possible cooperative effects on
tumorigenesis of germ-line mutations in Dcn and p53 we mated
animals homozygous for Dcn mutation with mice homozygous for
p53 mutation to obtain double heterozygous. These animals
subsequently were intercrossed to yield double mutant mice.
Mice lacking p53 are viable and fertile, but exhibit an increased
rate of tumor development and are also prone to genome
instability (21). In contrast, animals lacking the Dcn gene show no
overt tumor formation but exhibit a skin-fragility phenotype
because of the abnormal lateral fusion of collagen fibers (10). We
investigated the survival rate, tumor formation, and histopatho-
logical spectrum in three groups of animals: p531y1 Dcn2y2
(n 5 68), p532y2 Dcn2y2 (n 5 58), and p532y2 Dcn1y2
(n 5 28). The genotype of the animals was determined by PCR
analysis using specific primers for p53 and decorin genes and their
targeted alleles, respectively (Fig. 1). The animals were of mixed
genetic background with an average of 50% C57BLy6, 25%
129ySv, and 25% BlySwiss. Notably, the animals carrying a
wild-type p53 and a null decorin gene did not develop any tumor
for the 9-month period of observation (Fig. 2). In addition, we did
not observe any preferential tumor development in the p531y1
Dcn2y2 animals after nearly 2 years of observation. We noticed
the appearance of salivary gland hyperplasia in about 5% and a
few sporadic cases of hyperplasia of the gastric mucosa in older
animals (unpublished observation). Thus, lack of decorin expres-
sion alone does not predispose to tumor formation. In contrast,
by '4 months of age, '50% of the double knockout animals died
or were required to be sacrificed because of ill health (Fig. 2). By
5 months of age, '90% of the double knockout succumbed to
tumor growth. No difference between male and female occur-
rence was noted. As expected, the p532y2 Dcn1y2 animals
survived longer with 50% mean survival rate of '6 months,
similar to that observed in the p532y2 animals studied before
(16, 21–23). In contrast to a previous report (12), we did not
observe any increased incidence of infections, and this was
confirmed by careful autopsy of all the animals and histopathol-
ogy of several parenchymal organs.
Our data indicate that the combination of p53 and decorin
deficiency predisposes the animals to an accelerated mor-
tality because of enhanced tumorigenesis (see below). In
addition, the presence of a single decorin allele is sufficient
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to maintain a survival rate similar to that obtained when both
wild-type decorin alleles are present in the context of a p53
null genetic background (22).
The Predominant Tumor of Double Knockout Animals Is
Thymic Lymphoma. The spectrum of spontaneous tumors that
generally are observed in p532y2 animals includes T cell lym-
phomas (.60%), soft tissues sarcoma ('30%), and a variety of
neoplasms encompassing teratomas, brain tumors, and rare car-
cinomas (12, 13, 21). In contrast, the spectrum of tumors in the
p531y2 animals is different with osteosarcomas, soft tissue
sarcomas, and lymphomas in roughly equal proportions (21).
Moreover, p531y2 animals can develop classical carcinomas of
the lung and colon as well as tumors of the pituitary gland (21).
Another feature that is characteristic of both p531y2 and
p532y2 background is the occurrence of multiple histogeneti-
cally distinct tumors in the same mutant animal (11). In contrast,
the animals carrying both p53 and decorin null alleles showed a
remarkable homogeneity in tumor spectrum and exhibited es-
sentially no multiple tumors. More than 95% of the animals
developed lymphomas in the thymic region and thus involving
primarily the anterior mediastinum. Often the tumors encased
the heart, pericardium, and lungs and extended into the soft
tissues of the neck and chest wall. Because of the massive
mediastinal involvement, the mice died as a direct consequence
of pericardial compression or respiratory distress, in agreement
with previous studies (16). The spleen was rarely affected, pos-
sibly because of the rapid appearance of the thymic lymphomas
and the relatively shorter survival rate. In only one animal, a
high-grade hemangiosarcoma was identified in the submandib-
ular region. In a few ('5%) animals, no neoplasm was grossly
identified; however, histological evaluation showed marked en-
largement of the thymus and foci of atypical lymphocytes often
infiltrating the mediastinal soft tissues with signs of early-invading
malignant lymphomas harboring a similar phenotype (not
shown). The overall tumor spectrum in the p532y2 Dcn1y2
animals essentially was identical to that observed in the double
knockout animals.
Histopathological examination of the tumors revealed high-
grade lymphomas (Fig. 3A) with a starry-sky appearance. The
tumor cells infiltrated the soft tissues of mediastinum (Fig. 3 D
and J), the salivary glands (Fig. 3 E and F), the periaortic spaces
(Fig. 3G), the pericardium (Fig. 3H), and the bronchial wall (Fig.
3I). The microscopic features of these lymphomas were identical
in the p532y2 Dcn1y2 animals (Fig. 3L). The only nonlym-
phomatous tumor, a high-grade hemangiosarcoma, is shown in
Fig. 3K. Primary cultures of three independent thymic lympho-
mas reveled that the vast majority of the neoplastic cells reacted
with antibodies against murine CD4 and CD8 (Fig. 3 B and C),
indicating that they arose from the transformation of immature
thymocytes (13). Thus, the absence of decorin in a p53-deficient
genetic background accelerates lymphoma tumorigenesis. These
data suggest that decorin cooperates with p53 in allowing a rapid
appearance of the most common tumor in p532y2 animals. In
fact, the incidence of thymic lymphomas has been reported to
vary from 71 to 82% (11–13), depending on the genetic back-
ground (Table 1). The genetic background of our animals is
similar to that described by others (11, 13, 16). This supports the
notion that the shortened latency of lymphoma tumorigenesis is
linked directly to the absence of decorin rather than to a modifier
gene associated with a specific genetic background.
Absence of Decorin Is Permissive for the Growth of Lym-
phoma Cells. To investigate the role of decorin in lymphoma
tumorigenesis we isolated several clones from freshly minced
thymic lymphomas carrying both p53 and decorin null alleles.
After establishing the cultures and testing them for CD4 and CD8
reactivity (Fig. 3 B and C), we cultured one clone (designated
PD100) over a confluent monolayer of MEFs derived from either
wild-type or Dcn2y2 animals. Cell division of MEFs was ar-
rested by mitomycin C. Thus, the only difference between the two
sets of feeder layers was the synthesis and release of decorin
proteoglycan in the medium as shown by Western immunoblot-
ting using an antibody directed against the N terminus of mouse
decorin (24) (Fig. 4A). Notably, PD100 lymphoma cells grew
faster in the absence of decorin, and after 6 days of continuous
culture there were approximately four times more tumor cells
than control (Fig. 4B). These experiments were repeated twice
with similar results. Cell cycle analysis at each day of coculture
using fluorescence-activated cell sorting revealed no cell death or
significant block in G1 (not shown). The latter differs from our
previous results using attached tumor cells in which we found an
overall increase in the proportion of cells in the G1 phase of the
cell cycle in all the decorin-transfected clones (7). Thus, it appears
that decorin causes growth retardation in unattached lymphoma
FIG. 1. Genotyping strategy of mice harboring germ-line mutations in
p53 andyor decorin. (Upper) Schematic representations of the wild-type
and targeted alleles and the primer position for the p53 and decorin genes,
respectively. (Lower) Representative PCR products used to genotype
animals derived from the mating of p532y2 and Dcn2y2 mutant mice.
The germ-line mutation of p53 and Dcn consists of an insertion of
PolII-neo or PGK-neo in the fifth and second exon of their respective
genes. Three separate sets of PCR amplifications were performed for
each individual offspring and confirmed by DNA sequencing. The
genotype is indicated at the top of the ethidium bromide-stained agarose
gels, and the molecular weight in bp is indicated in the right margins.
FIG. 2. Survival curve of mice harboring germ-line mutations in p53
andyor decorin. The graph summarizes the survival of p532y2 Dcn2y2
(F, n 5 58) relative to p532y2 Dcn1y2 (E, n 5 28), and p531y1
Dcn2y2 (, n 5 68). The mean survival age (T50) was '4 and '6 months
for the p532y2 Dcn2y2 and p532y2 Dcn1y2 genotype, respectively.
None of the p531y1 Dcn2y2 animals developed tumors or needed to
be sacrificed for ill health during the 9-month period of observation.
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cells without causing a block of cell cycle progression but, rather,
with a slowing down of the cell cycle.
To further investigate these effects, we cultured PD100 lym-
phoma cells in the presence of 1 mM recombinant human decorin
or its protein core. The results showed a significant inhibition of
growth (Fig. 4C), and the core protein exhibited a greater
cytostatic effect than the proteoglycan (Fig. 4D). These data, thus,
demonstrate that the inhibitory activity resides in the protein
moiety rather than the dermatan sulfate chains and indicate
further that these cytostatic properties of decorin transcend
FIG. 3. Gallery of digitized images illustrating the morphology of tumors in p53yDcn double mutant animals. Histopathological examination of the
tumors revealed high-grade lymphoma (A). B and C represent cytospin preparations of the cultured PD100 lymphoma shown in A after immunostaining
with anti-CD4 and anti-CD8 antibodies. The tumor cells are highly invasive and infiltrate the soft tissues of mediastinum (D and J), the salivary glands
(E and F), the periaortic spaces (G), the pericardium (H), and the bronchial wall (I). K shows a section of the only nonlymphoid tumor, a high-grade
hemangiosarcoma, found in a double mutant animal. L is a section of a thymic lymphoma detected in the p532y2 Dcn1y2 animals showing microscopic
features identical to those observed in the double mutant animals. The images were digitized with a Pixera digital camera at resolution of '106 pixelsyinch.
[3150 (A, F, I, J, L); 3300 (B, C, K); 3100 (D, E, G, H).]
Table 1. Frequency of lymphomas in mice lacking p53 or decorin alleles vis-a`-vis those lacking p53 alone in various genetic backgrounds
Genotype Genetic background (estimated proportion)
Incidence of thymic lymphomas
(n 5 total number) Reference
p532y2 Dcn2y2 C57Bly6, 129ySv, BlySwiss (50%, 25%, 25%) 95% (n 5 58) This study
p532y2 Dcn1y2 C57Bly6, 129ySv, BlySwiss (50%, 25%, 25%) 94% (n 5 28) This study
p532y2 Dcn1y1 C57Bly6, 129ySv (75%, 25%) 77% (n 5 26) Donehower et al. (11)
p532y2 Dcn1y1 129ySv (100%) 65% (n 5 26) Harvey et al. (22)
p532y2 Dcn1y1 C57BLy6, 129ySv (75%, 25%) 70% (n 5 44) Harvey et al. (22)
p532y2 Dcn1y1 129ySv (100%) 47% (n 5 43) Donehower et al. (16)
p532y2 Dcn1y1 C57Bly6, 129ySv ('50%, 50%) 71% (n 5 55) Jacks et al. (13)
p532y2 Dcn1y1 129yOla ('50%, 50%) 82% (n 5 17) Purdie et al. (12)
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species because human decorin can suppress the growth of
murine thymic lymphoma cells.
Ectopic Expression of Decorin Reduces Colony Formation in
the Thymic Lymphoma Cells. Because the double knockout
tumor cell lines were resistant to neomycin, we first electropo-
rated the PD100 clone with the full-length mouse decorin using
a pCDNA3.1yZeo(1) vector. However, several transfection ex-
periments proved unsuccessful. For this reason, we used a ret-
rovirus-based approach. The full-length mouse decorin cDNA
was subcloned into the EcoRI restriction site of LXSP retroviral
vector, which carries the puromycin resistance gene driven by the
simian virus 40 early promoter. The expression of decorin is
under the control of the long terminal repeat of the mouse
Maloney virus (20). About 2.5 3 106 PD100 T cell lymphoma cells
obtained from the p532y2 Dcn2y2 double knockout mice were
infected with the retrovirus carrying the full-length decorin
(LXSP-Decorin) or with the empty LXSP retroviral vector as
described before (20, 25). Proper expression of decorin was tested
by immunoblotting of medium conditioned for 2–3 days by the
total cells before plating (not shown). Three days postinfection,
5 3 104 viable cells were plated in semisolid medium in the
presence of 2 mgyml puromycin. After 12 days of selection in
puromycin, the number of puromycin-resistant colonies arising
from the decorin-infected cells was markedly diminished (.75%
inhibition) as compared with that of cells infected with the vector
alone (Fig. 5). Thus, ectopic expression of decorin reduces
colony-forming ability of lymphoma cells. Collectively, the data
presented above point to a primary role of decorin in malignancy
and establish a functional synergism in lymphoma tumorigenesis
dependent on the effects of a natural inhibitor of tumor cell growth
(that we call ‘‘extracellular tumor repressor’’) in a genetic back-
ground deficient of intracellular p53 (‘‘tumor-suppressor’’) gene.
DISCUSSION
This study tests the function of a secreted proteoglycan and a
tumor-suppressor gene in the process of spontaneous in vivo
tumorigenesis. Our findings indicate that lack of decorin in an
otherwise wild-type background is not sufficient by itself to
induce tumorigenesis. However, the lack of decorin in a p53 null
background accelerates the appearance of tumors, essentially all
T cell-derived lymphomas. We do not know whether the selective
appearance of lymphomas is due solely to an acceleration of the
‘‘usual’’ tumorigenic process observed in the p53 null animals
because these mutant animals spontaneously develop thymic
lymphomas at high frequency (21). An interesting hypothesis is
related to the existence of various temporal windows of oppor-
tunity for tissue-specific tumor development (16). During neo-
natal stages, for example, the highest rate of cell division and
potential genetic rearrangement is the lymphoid compartment. In
the thymus, decorin is localized primarily in the capsule and the
fibrovascular septa (26). Thus, the absence of functional p53 and
decorin may allow a faster accumulation of genetic abnormalities
and also may favor tumor progression in the lymphoid system.
The observation of thymic hyperplasia and foci of lymphoid
atypia in cases in which no overt tumor was found further supports
the concept that absence of decorin in a p53 null genetic back-
ground favors lymphomagenesis. Reactive lymphoid hyperplasia
also has been observed in mice carrying a large deletion of the p53
gene (12) and at a lower frequency in exon 5 mutant mice (11).
Specific genetic backgrounds play a role in the manifestation of
tumors affecting both the rate and spectrum of neoplastic devel-
opment in the mutant animals (23). Normal C57BLy6 mice have
a relatively high incidence of lymphomas, but the average age of
onset is about 27 months (23). Because '75% of the C57BLy6,
129ySv p53 2y2 animals developed lymphomas, it was hypoth-
esized initially that the high incidence of this type of malignancy
might be a result of a specific genetic background of the inbred
animals (11). In a subsequent study, however, it was discovered
that in a pure 129ySv strain, loss of p53 causes a high incidence
(65%) of lymphomas (23), although the frequency and type of
FIG. 4. Decorin inhibits the growth of PD100 thymic lymphoma cells
derived from p532y2 Dcn2y2 animals. (A) Western immunoblotting of
serum-free medium conditioned by embryonic fibroblasts derived from
Dcn1y1 and Dcn2y2 mouse embryos (MEF) using LF-113 polyclonal
antibody directed against a synthetic peptide in the N terminus of decorin
spanning residues 36–49 of the mouse protein core (24). The migration
of the molecular mass markers is indicated in the left margin. Under such
conditions, decorin migrates as a smear centering around 100 kDa (10).
(B) Growth of PD100 thymic lymphoma cells in the presence or absence
of a feeder layer composed by mitomycin-arrested MEFs. The genotype
is indicated in the top margin. (C and D) Growth of PD100 thymic
lymphoma cells cultured in the absence or presence of recombinant
human decorin or its protein core (1 mM each). Cells were counted after
60 hr of culture in 5% FBS. The values represent the mean of quadru-
plicate determinations 6SEM.
FIG. 5. Inhibition of PD100 colony formation by ectopic decorin
expression. Colonies from 5 3 104 freshly infected PD100 thymic
lymphoma cells were grown in methyl cellulose in the presence of
puromycin (2 mgyml) and scored 12 days later. Mock, noninfected
cells; LXSP, cells infected with the empty vector LXSP; LSXP-Dcn,
cells infected with the retrovirus carrying the full-length mouse
decorin cDNA. Error bars indicate 6SD of the mean of four inde-
pendent experiments performed in duplicate. Notice the marked
suppression of colony-forming ability in the decorin-expressing clones.
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other tumors were markedly different from the mixed-
background mice (summarized in Table 1). Thus, lymphoma
development appears to be directly linked to p53 loss and is not
a strain-specific effect. It has been proposed that p53 plays a key
role in the surveillance of gene amplification, abnormal recom-
bination events, and the control of ploidy (27). The development
of thymic lymphomas in the p53 nullizygous mice (11) and the
role p53 plays in controlling T cell recombination events (28)
support these concepts.
Our findings also indicate that although the survival rate of the
p532y2 Dcn1y2 was not significantly different from that of
p532y2 Dcn1y1 animals, the mice lacking one decorin allele
showed the same type of lymphomas in 94% of the cases. We have
not investigated the loss of heterozygosity in the tumors because
decorin is not expressed by the neoplastic cells but, rather, by the
stromal elements. We have noticed previously, however, that the
levels of decorin were relatively low in the heterozygous animals
although with some degree of variability (10). In addition, we
observed that there was no compensatory mechanism and that
the homologous proteoglycan biglycan was not increased in its
expression. Thus, reduced expression of decorin also may help to
accelerate the appearance of malignant lymphoma. Alternatively,
decorin expression may be directly related to lymphoma tumor-
igenesis. To address this question more directly, we isolated
lymphoma cells from tumors of double knockout animals and
infected them with a retrovirus expression vector containing the
full-length mouse decorin. The data clearly showed a marked
inhibition of colony formation in methylcellulose when decorin
was expressed. Moreover, the growth of wild-type lymphoma cells
from the double knockout animals was markedly reduced when
the cells were cultured on top of a feeder layer composed of
Dcn1y1 embryonic fibroblasts vis-a`-vis Dcn2y2 fibroblasts.
Because the only difference between the two fibroblast feeder
layers was the presence of secreted decorin, we conclude that
absence of decorin is permissive for the in vitro growth of thymic
lymphoma cells. If decorin does not affect the cell cycle in these
thymic lymphoma cells (as our data indicate) but does retard the
overall growth of the tumor cells, then it is possible that in vivo
the reduced rate of mitosis may attenuate or delay the rate of
mutations in a p53-deficient genetic background.
The cytostatic effects of murine decorin in coculture settings
were corroborated by experiments in which recombinant human
decorin proteoglycan or its protein core caused a marked inhi-
bition of growth in thymic lymphoma cells isolated from double
mutant animals. Interestingly, the protein core exhibited a greater
cytostatic effect than the proteoglycan itself, indicating that the
inhibitory activity resides in the protein moiety rather than the
dermatan sulfate side chains. Our findings indicate further that
the cytostatic properties of decorin transcend species because
human decorin can suppress the growth of murine thymic lym-
phoma cells. This is in agreement with our previous data in which
we found growth suppression of mouse M2 melanoma cells upon
stable transfection with a human decorin cDNA (7).
To assess cooperativity between p53 and other tumor-
associated genes, several investigators have crossed p53-deficient
mice to other strains of tumor-susceptible transgenic or knockout
mice (21). Among these studies, two reports have shown an
accelerated lymphomagenesis. First, double mutant animals lack-
ing both p53 and the catalytic subunit of DNA protein kinase at
the scid locus (p53 scid) resulted in the development of lymphoma
with strikingly early onset (29). Second, mice lacking p53 and
either Rag1 or Rag2 genes, which are needed for V(D)J recom-
bination, developed thymic lymphomas at high frequency (70 and
86% of total, respectively), and the tumor arose with a short
latency (30). In both sets of bitransgenic animals, the mortality
rate and the spectrum of tumors were nearly identical to those
observed in the p532y2 Dcn2y2 mice. In contrast, mice
deficient in both p53 and Rb genes show an accelerated tumor-
igenesis but also a different spectrum of tumors not observed in
the parental singly deficient animals, including pinealoblastomas,
islet cell tumors, and other neuroendocrine neoplasms of the
thyroid and pituitary glands (22, 31). Thus, it is possible that
germ-line mutations of both p53 and Dcn genes may cooperate in
the transformation of thymic lymphocytes.
Another possibility to be considered is that decorin may be
involved in modulating the immune response. A recent study has
shown in an animal model of brain tumor that ectopic expression
of decorin in C6 rat glioma cells results in a strong inhibition of
tumor formation in vivo (32). Notably, the decorin-expressing
glioma cells show a marked increase in activated T lymphocytes
infiltrating the tumors, and these effects can be abrogated by
steroid-mediated immune suppression. Thus, ectopic expression
of decorin significantly enhances antiglioma immune response in
vivo.
In conclusion, this study provides genetic evidence that
decorin, a natural inhibitor of tumor growth, plays an important
role in restraining thymic lymphoma cells from rapidly infiltrating
the mediastinal soft tissues. The potential cooperation of two
genes, one acting on the transcriptional machinery within the
nucleus (an established ‘‘tumor-suppressor gene’’) and one acting
at the cellymatrix boundary (which we term ‘‘extracellular tumor-
repressor gene’’), opens new avenues of research and novel,
potential therapeutic approaches.
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